Allogene Therapeutics Inc... (ALLO)
Allogene Therapeutics Inc. (ALLO) Stock Price, Analysis & Data
| Bid | 1.53 |
| Market Cap | 714.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -173.76M |
| Beta | 0.47 |
| EPS (ttm) | -0.77 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.03 |
| P/B (ttm) | 1.82 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 12, 2026 |
| Ask | 2.63 |
| Volume | 4,376,091 |
| Avg. Volume (20D) | 8,070,520 |
| Open | 2.13 |
| Previous Close | 2.12 |
| Day's Range | 2.05 - 2.15 |
| 52-Week Range | 0.99 - 4.46 |
| Analyst | Strong Buy |
| Price Target | 9 (334.78%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ALLO
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansege...
Financial Performance
In 2025, Allogene Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 22K. Earnings were -190.89M, a decrease of -25.9%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for ALLO stock is "Strong Buy". The 12-month stock price forecast is 9, which is upside of 334.78% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
